{
  "id": 5063409,
  "title": "Adressing complicated pregnancies, iPremom raises €15 million to advance early detection",
  "url": "https://urgent.news/2026/09/02/adressing-complicated-pregnancies-ipremom-raises-15-million-to",
  "topic": "business",
  "section": "Business",
  "published": "2026-09-02T10:15:00.000Z",
  "source": {
    "name": "EU-Startups",
    "slug": "eu-startups",
    "url": "https://www.eu-startups.com/2026/09/adressing-complicated-pregnancies-ipremom-raises-e15-million-to-advance-early-detection/"
  },
  "original_language": "en",
  "account": "Spanish molecular diagnostics firm iPremom has secured €15 million in Seed funding to advance its early detection platform for pregnancy complications. The round was led by Amadeus Capital Partners, with participation from Asabys Partners and APEX Ventures.\n\niPremom's MaiRa platform analyzes early signals of pregnancy complications through blood tests, aiming for comprehensive early molecular imaging of pregnancies. Professor Carlos Simón, co-founder and Chairman of iPremom, emphasizes the lack of timely diagnosis and treatment of pregnancy complications, stating their ambition extends beyond creating a superior preeclampsia test.\n\nThe investment comes amid a surge in European funding for molecular diagnostics, women's health, and early disease detection in 2026. Recent financings include €5 million for En Carta Diagnostics, €1.1 million for Intu Diagnostics, €1.7 million for KOVE Medical, and €5.2 million for DITTO, among others.\n\nAI and biomarker-led diagnostics have also attracted capital, with €2.8 million for Moonlight AI and €17.1 million for Lucis. For iPremom, the funding is crucial for clinical validation and commercial rollout of the MaiRa platform, built on over a decade of research. The platform leverages more than 26,000 patient samples linked to 10,000 pregnancies from the PREMOM study to identify molecular signals of pregnancy complications like preeclampsia, pre-term birth, and gestational diabetes.\n\nPregnancy complications claim 260,000 maternal lives, nearly 2 million stillbirths, and 2.3 million infant deaths annually. Current diagnostic tools often fail to detect risks until complications have already begun. iPremom is preparing for further regulatory approvals in the EU and USA.",
  "summary": "iPremom, a Spanish molecular diagnostics company addressing the early identification of pregnancy complications, has raised €15 million in Seed funding to support clinical validation and the commercial rollout of its MaiRa platform, which analyses early signals of first-trimester pregnancy complications through blood tests. The round was led by Amadeus Capital Partners, with participation from…",
  "key_points": [
    "Spanish firm iPremom raises €15 million in Seed funding",
    "MaiRa platform analyzes blood tests for pregnancy complications",
    "Investment aims for clinical validation and commercial rollout"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}